Kelun Biotech, a subsidiary of Shenzhen-listed Kelun Pharmaceutical, has secured over 500 million yuan ($77 million) in fresh funding led by CMC-SDIC Capital, a fund co-launched by state-backed China Merchants Capital and SDIC, the lead investor announced on Thursday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
